PB 37 of 2013
National Health (Weighted average disclosed price – main disclosure cycle) Amendment Determination 2013 (No. 2)
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this amendment determination under subsection 99ADB(4) of the National Health Act 1953.
Dated     4   July 2013
 
 
 
 
 
 
 
 
 
FELICTY McNEILL
 
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price – main disclosure cycle) Amendment Determination 2013 (No. 2).
       (2)     This Determination may also be cited as PB 37 of 2013.
2              Commencement
                This Determination commences on the day after it is registered.
 
 
3              Amendments to PB 26 of 2013
Schedule 1 amends the National Health (Weighted average disclosed price – main disclosure cycle) Determination 2013 (No. 1) (PB 26 of 2013).
Schedule 1             Amendments
 
 
[1]      Schedule 1
omit:
 
317
Etoposide
Powder for I.V. infusion 1 g (as phosphate)
Injection
Etopophos
174.65
 
Insert:
 
317
Etoposide
Powder for I.V. infusion 1 g (as phosphate)
Injection
Etopophos
174.62
 
 
             omit:
 
319
Etoposide
Solution for I.V. infusion 100 mg in 5 mL vial
Injection
Etoposide Ebewe
17.47
 
insert:
 
319
Etoposide
Solution for I.V. infusion 100 mg in 5 mL vial
Injection
Etoposide Ebewe
87.33
 
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au/Home.